Form 4: Ocular Therapeutix Executive Chairman Sells Shares to Cover Tax Obligations

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold 21,475 shares of common stock on February 24, 2025.
• The sale was executed at a weighted average price of $6.87 per share, with individual transactions ranging from $6.79 to $6.97.
• The sale was conducted under a pre-arranged automatic sale instruction adopted on February 21, 2024, to cover tax withholding obligations related to the vesting of restricted stock units on February 22, 2025.
• Following the transaction, Dugel still beneficially owns 3,520,318 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Insider sales are a common occurrence, especially when executives exercise stock options or restricted stock units. These sales are often planned in advance to comply with insider trading regulations.

Stakeholder Impact

• The sale of shares by a high-ranking executive could potentially create short-term uncertainty among shareholders, although the stated reason for the sale (tax obligations) mitigates this concern.

Key Dates